Gene:
YWHAQ
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, theta polypeptide

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

Overview

Alternate Names:  protein tau; tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, theta polypeptide
Alternate Symbols:  14-3-3; HS1
PharmGKB Accession Id: PA37443

Details

Cytogenetic Location: chr2 : p25.1 - p25.1
GP mRNA Boundary: chr2 : 9724106 - 9771106
GP Gene Boundary: chr2 : 9721106 - 9781106
Strand: minus

Visualization

UCSC has a Genome Browser that you can use to view PharmGKB annotations for this gene in context with many other sources of information.

View on UCSC Browser
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

PharmGKB contains no curated pathways for this gene. If you would like to volunteer to work on a pathway, please let us know.

External Pathways

Links to non-PharmGKB pathways.

  1. Role of Calcineurin-dependent NFAT signaling in lymphocytes - (Pathway Interaction Database NCI-Nature Curated)

Publications related to YWHAQ: 1

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CASP8 SNP D302H (rs1045485) Is Associated with Worse Survival in MYCN-Amplified Neuroblastoma Patients. PloS one. 2014. Rihani Ali, et al. PubMed

LinkOuts

Entrez Gene:
10971
OMIM:
609009
UCSC Genome Browser:
NM_006826
RefSeq RNA:
NM_006826
RefSeq Protein:
NP_006817
RefSeq DNA:
AC_000045
AC_000134
NC_000002
NT_005334
NW_001838766
NW_927719
UniProtKB:
1433T_HUMAN (P27348)
Ensembl:
ENSG00000134308
GenAtlas:
YWHAQ
GeneCard:
YWHAQ
MutDB:
YWHAQ
ALFRED:
LO032156R
HuGE:
YWHAQ
Comparative Toxicogenomics Database:
10971
ModBase:
P27348
HumanCyc Gene:
HS05854
HGNC:
12854

Common Searches